Navigating Global Pharma Policy
Navigate the intricate dynamics of tariffs on the global pharmaceutical industry through this insightful content series. With contributions from A&M experts on both sides of the Atlantic, this series explores the economic, operational, and legal challenges posed by international trade policies. From the potential disruption of global supply chains to the strategic responses of leading pharmaceutical companies, A&M's Global Life Sciences team offers a comprehensive analysis of how the industry is navigating this evolving landscape.
Gain valuable perspectives on financial optimization, supply chain resilience, and regulatory compliance, as well as the broader geopolitical implications of these tariffs. Whether you're a stakeholder in the pharmaceutical sector or simply interested in the intersection of trade and healthcare, this series provides actionable insights and thought leadership from professionals deeply embedded in the industry.
Working Capital, Technology and Regulatory Implications of Localised Manufacturing
Pharma’s Supply Chain Reset
As global trade pressures drive a shift from globalised to localised supply chains, the pharmaceutical industry faces a host of new challenges. The move to relocate production from Asia and Europe to North America comes with significant operational, financial and strategic implications, including increased regulatory complexity, the technical demands of technology transfer, higher working capital requirements, and the need to rethink production economics.
To protect margins and liquidity in this environment, some companies are further enhancing their investments in advanced manufacturing, including disposable bioreactors, modular “factory-in-a-container” solutions, continuous manufacturing techniques, and AI-driven analytics engines. Historically slow to adopt such innovations, the biopharma sector may now be forced to accelerate change.
Stay informed as we continue to explore the evolving landscape of U.S. trade policies and their impact on the global pharmaceutical industry. This series will be updated regularly to reflect the latest developments, offering fresh insights and strategies to navigate the challenges ahead. Follow along as we analyze policy shifts, industry responses, and the broader implications for global healthcare and trade.
